Be Aware Canagliflozin Might Increase Amputation Risk in Diabetes Patients

July 2017

Reports of amputation with canagliflozin (Invokana, Invokamet) will raise more questions about the safety of SGLT2 inhibitors.

This is the latest in a growing list of "flozin" concerns...ketoacidosis, urinary tract infections, yeast infections, etc.

Amputations, mainly of the toe or mid-foot, are seen in about 6 in 1,000 patients taking canagliflozin per year...compared to about 3 in 1,000 patients per year on other diabetes meds.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Med Adherence Take Steps to Reduce the Number of Return-to-Stock Rxs
Antipsychotics Think of Rexulti as Similar to Abilify
Pediatrics Ask for a Child's Weight at Drop-Off...Even for Refills
Transdermal Patches Help Avoid Common Errors With Transdermal Patches
Opioids Implement Strategies to Help Ensure Opioids Are Used Properly
Corticosteroids Expect to See Fewer Rxs for Short Courses of Oral Steroids
Diabetes Be Aware Canagliflozin Might Increase Amputation Risk in Diabetes Patients
Osteoporosis Stay Alert for Mix-Ups With Meds for Treating Osteoporosis
UTIs Be Prepared to Handle Unusual Antibiotic Rxs for Recurrent UTIs
Heart Failure Prevent Mishaps With Entresto or Lancora in Heart Failure Patients
Musculoskeletal Look for Meds Linked to Nighttime Leg Cramps

Be Aware Canagliflozin Might Increase Amputation Risk in Diabetes Patients

Practical advice for a better career, with unlimited access to CE

Table of Contents